Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Research Article

Loperamide-induced Constipation Activates Inflammatory Signaling Pathways in the Mid Colon of SD Rats Via Complement C3 and its Receptors

Author(s): Yun Ju Choi, Ji Eun Kim, Su Jin Lee, Jeong Eun Gong, Miran Jang, Jin Tae Hong and Dae Youn Hwang*

Volume 22, Issue 5, 2022

Published on: 24 August, 2021

Page: [458 - 469] Pages: 12

DOI: 10.2174/1566524021666210618124220

open access plus

Abstract

Background: Complement component 3 (C3) receptors play an important role as inflammatory mediators in the innate immune system, although their mechanisms were not well studied during constipation.

Objective: The aim of this study is to investigate the regulatory role of C3 and its receptors' downstream signaling during constipation.

Methods: Alterations in the C3, C3a receptor (C3aR), and C3b receptor (C3bR) expressions, PI3K/AKT pathway, RhoA/MLC pathway, MAP kinase pathway, and inflammatory cytokine expressions were measured in the mid colon of loperamide (Lop) treated SD rats.

Results: Lop treatment successfully induced constipation phenotypes, including decreased stool parameters and histological structure alterations. The expression levels of C3 were significantly increased, whereas expressions of C3aR and C3bR were decreased during Lop-induced constipation. Moreover, significant upregulation was observed in the phosphorylation levels of PI3K, AKT, and GSK3β in mid colons of Lop treated SD rats. The expression of RhoA and phosphorylation of MLC were also enhanced in the Lop treated group. Furthermore, a similar pattern was detected in the MAP kinase pathway and inflammatory cytokine expressions. Subsequent to the Lop treatment, the phosphorylation of ERK and p38, as well as the mRNA levels of NF-κB, TNF-α, IL-6 and IL-1α were remarkably increased in the mid colon.

Conclusion: These results indicate that Lop-induced constipation is tightly linked to the downregulation of C3aR and C3bR expressions, and upregulation of the C3 and C3Rs downstream signaling pathway, including PI3K/AKT, RhoA/MLC, and MAP kinase pathways as well as inflammatory cytokine expressions in the mid colon of SD rats.

Keywords: Complement C3, Constipation, C3a receptor, C3b receptor, PI3K/AKT pathway, Loperamide.

« Previous
[1]
Venkatesha RT, Berla Thangam E, Zaidi AK, Ali H. Distinct regulation of C3a-induced MCP-1/CCL2 and RANTES/CCL5 production in human mast cells by extracellular signal regulated kinase and PI3 kinase. Mol Immunol 2005; 42(5): 581-7.
[http://dx.doi.org/10.1016/j.molimm.2004.09.009] [PMID: 15607817]
[2]
Ehrnthaller C, Ignatius A, Gebhard F, Huber-Lang M. New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med 2011; 17(3-4): 317-29.
[http://dx.doi.org/10.2119/molmed.2010.00149] [PMID: 21046060]
[3]
Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11(9): 785-97.
[http://dx.doi.org/10.1038/ni.1923] [PMID: 20720586]
[4]
Li K, Fazekasova H, Wang N, et al. Functional modulation of human monocytes derived DCs by anaphylatoxins C3a and C5a. Immunobiology 2012; 217(1): 65-73.
[http://dx.doi.org/10.1016/j.imbio.2011.07.033] [PMID: 21855168]
[5]
Dalmasso AP, Falk RJ, Raij L. The pathobiology of the terminal complement complexes. Complement Inflamm 1989; 6(1): 36-48.
[http://dx.doi.org/10.1159/000463070] [PMID: 2650989]
[6]
Reis ES, Mastellos DC, Hajishengallis G, Lambris JD. New insights into the immune functions of complement. Nat Rev Immunol 2019; 19(8): 503-16.
[http://dx.doi.org/10.1038/s41577-019-0168-x] [PMID: 31048789]
[7]
Monsinjon T, Gasque P, Chan P, Ischenko A, Brady JJ, Fontaine MC. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 2003; 17(9): 1003-14.
[http://dx.doi.org/10.1096/fj.02-0737com] [PMID: 12773483]
[8]
Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol 2013; 190(8): 3839-47.
[http://dx.doi.org/10.4049/jimmunol.1203200] [PMID: 23564578]
[9]
Doepper S, Kacani L, Falkensammer B, Dierich MP, Stoiber H. Complement receptors in HIV infection. Curr Mol Med 2002; 2(8): 703-11.
[http://dx.doi.org/10.2174/1566524023361826] [PMID: 12462391]
[10]
Park JW, Kim JE, Choi YJ, et al. Deficiency of complement component 3 may be linked to the development of constipation in FVB/N-C3em1Hlee/Korl mice. FASEB J 2021; 35(1): e21221.
[http://dx.doi.org/10.1096/fj.202000376R] [PMID: 33337564]
[11]
Sugihara T, Kobori A, Imaeda H, et al. The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease. Clin Exp Immunol 2010; 160(3): 386-93.
[http://dx.doi.org/10.1111/j.1365-2249.2010.04093.x] [PMID: 20089077]
[12]
Ahrenstedt O, Knutson L, Nilsson B, Nilsson-Ekdahl K, Odlind B, Hällgren R. Enhanced local production of complement components in the small intestines of patients with Crohn’s disease. N Engl J Med 1990; 322(19): 1345-9.
[http://dx.doi.org/10.1056/NEJM199005103221903] [PMID: 2325733]
[13]
Riordan SM, McIver CJ, Thomas MC, et al. The expression of complement protein 4 and IgG3 in luminal secretions. Scand J Gastroenterol 1996; 31(11): 1098-102.
[http://dx.doi.org/10.3109/00365529609036893] [PMID: 8938903]
[14]
Halstensen TS, Mollnes TE, Garred P, Fausa O, Brandtzaeg P. Surface epithelium related activation of complement differs in Crohn’s disease and ulcerative colitis. Gut 1992; 33(7): 902-8.
[http://dx.doi.org/10.1136/gut.33.7.902] [PMID: 1379568]
[15]
Ueki T, Mizuno M, Uesu T, et al. Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC). Clin Exp Immunol 1996; 104(2): 286-92.
[http://dx.doi.org/10.1046/j.1365-2249.1996.17721.x] [PMID: 8625522]
[16]
Lin F, Spencer D, Hatala DA, Levine AD, Medof ME. Decay-accelerating factor deficiency increases susceptibility to dextran sulfate sodium-induced colitis: role for complement in inflammatory bowel disease. J Immunol 2004; 172(6): 3836-41.
[http://dx.doi.org/10.4049/jimmunol.172.6.3836] [PMID: 15004190]
[17]
Hughes S, Higgs NB, Turnberg LA. Loperamide has antisecretory activity in the human jejunum in vivo. Gut 1984; 25(9): 931-5.
[http://dx.doi.org/10.1136/gut.25.9.931] [PMID: 6590431]
[18]
Sohji Y, Kawashima K, Shimizu M. Pharmacological studies of loperamide, an anti-diarrheal agent. II. Effects on peristalsis of the small intestine and colon in guinea pigs (author’s transl) Nippon Yakurigaku Zasshi 1978; 74(1): 155-63.
[http://dx.doi.org/10.1254/fpj.74.155] [PMID: 640534]
[19]
Yamada K, Onoda Y. Comparison of the effects of T-1815, yohimbine and naloxone on mouse colonic propulsion. J Smooth Muscle Res 1993; 29(2): 47-53.
[http://dx.doi.org/10.1540/jsmr.29.47] [PMID: 8318729]
[20]
Lee HY, Kim JH, Jeung HW, et al. Effects of Ficus carica paste on loperamide-induced constipation in rats. Food Chem Toxicol 2012; 50(3-4): 895-902.
[http://dx.doi.org/10.1016/j.fct.2011.12.001] [PMID: 22178225]
[21]
Méité S, Bahi C, Yéo D, Datté JY, Djaman JA, N’guessan DJ. Laxative activities of Mareya micrantha (Benth.) Müll. Arg. (Euphorbiaceae) leaf aqueous extract in rats. BMC Complement Altern Med 2010; 10: 7.
[http://dx.doi.org/10.1186/1472-6882-10-7] [PMID: 20158903]
[22]
Wintola OA, Sunmonu TO, Afolayan AJ. The effect of Aloe ferox Mill. in the treatment of loperamide-induced constipation in Wistar rats. BMC Gastroenterol 2010; 10: 95.
[http://dx.doi.org/10.1186/1471-230X-10-95] [PMID: 20723249]
[23]
Bustos D, Ogawa K, Pons S, Soriano E, Bandi JC, Bustos Fernández L. Effect of loperamide and bisacodyl on intestinal transit time, fecal weight and short chain fatty acid excretion in the rat. Acta Gastroenterol Latinoam 1991; 21(1): 3-9.
[PMID: 1811403]
[24]
Yang ZH, Yu HJ, Pan A, et al. Cellular mechanisms underlying the laxative effect of flavonol naringenin on rat constipation model. PLoS One 2008; 3(10): e3348.
[http://dx.doi.org/10.1371/journal.pone.0003348] [PMID: 18833323]
[25]
Kim JE, Park JW, Kang MJ, et al. Anti-inflammatory response and muscarinic cholinergic regulation during the laxative effect of Asparagus cochinchinensis in loperamide-induced constipation of SD rats. Int J Mol Sci 2019; 20(4): 946.
[http://dx.doi.org/10.3390/ijms20040946] [PMID: 30795644]
[26]
Kim JE, Park JW, Kang MJ, et al. Laxative effect of Spicatoside A by cholinergic regulation of enteric nerve in loperamide-induced constipation. ICR Mice Model Molecules 2019; 24(5): 896.
[http://dx.doi.org/10.3390/molecules24050896] [PMID: 30836659]
[27]
Kim JE, Song BR, Yun WB, et al. Correlation between laxative effects of uridine and suppression of ER stress in loperamide induced constipated SD rats. Lab Anim Res 2017; 33(4): 298-307.
[http://dx.doi.org/10.5625/lar.2017.33.4.298] [PMID: 29399027]
[28]
Kim JE, Go J, Sung JE, et al. Laxative effects of Liriope platyphylla are tightly correlated with suppression of endoplasmic reticulum stress in loperamide-induced constipation of SD rats. Lab Anim Res 2016; 32(1): 16-23.
[http://dx.doi.org/10.5625/lar.2016.32.1.16] [PMID: 27051439]
[29]
Kim JE, Lee YJ, Kwak MH, Ko J, Hong JT, Hwang DY. Aqueous extracts of Liriope platyphylla induced significant laxative effects on loperamide-induced constipation of SD rats. BMC Complement Altern Med 2013; 13: 333.
[http://dx.doi.org/10.1186/1472-6882-13-333] [PMID: 24274470]
[30]
Kim JE, Go J, Sung JE, et al. Uridine stimulate laxative effect in the loperamide-induced constipation of SD rats through regulation of the mAChRs signaling pathway and mucin secretion. BMC Gastroenterol 2017; 17(1): 21.
[http://dx.doi.org/10.1186/s12876-017-0576-y] [PMID: 28122499]
[31]
Park JW, Kim JE, Kang MJ, et al. Anti-oxidant activity of gallotannin-enriched extract of galla rhois can associate with the protection of the cognitive impairment through the regulation of BDNF signaling pathway and neuronal cell function in the scopolamine-treated ICR mice. Antioxidants 2019; 8(10): 450.
[http://dx.doi.org/10.3390/antiox8100450] [PMID: 31623364]
[32]
Sacks SH, Zhou W. The role of complement in the early immune response to transplantation. Nat Rev Immunol 2012; 12(6): 431-42.
[http://dx.doi.org/10.1038/nri3225] [PMID: 22627861]
[33]
Schmudde I, Laumonnier Y, Köhl J. Anaphylatoxins coordinate innate and adaptive immune responses in allergic asthma. Semin Immunol 2013; 25(1): 2-11.
[http://dx.doi.org/10.1016/j.smim.2013.04.009] [PMID: 23694705]
[34]
Hanania NA, Cazzola M. Bronchodilators: Beta2-Agonists and Anticholinergics. Philadelphia, PA, USA: Elsevier Inc 2008.
[35]
Rajagopal S, Shenoy SK. GPCR desensitization: Acute and prolonged phases. Cell Signal 2018; 41: 9-16.
[http://dx.doi.org/10.1016/j.cellsig.2017.01.024] [PMID: 28137506]
[36]
Uotani S, Bjørbaek C, Tornøe J, Flier JS. Functional properties of leptin receptor isoforms: internalization and degradation of leptin and ligand-induced receptor downregulation. Diabetes 1999; 48(2): 279-86.
[http://dx.doi.org/10.2337/diabetes.48.2.279] [PMID: 10334302]
[37]
Ronnett GV, Knutson VP, Lane MD. Insulin-induced down-regulation of insulin receptors in 3T3-L1 adipocytes. Altered rate of receptor inactivation. J Biol Chem 1982; 257(8): 4285-91.
[http://dx.doi.org/10.1016/S0021-9258(18)34719-7] [PMID: 7040381]
[38]
Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol 2012; 4(9): a011189.
[http://dx.doi.org/10.1101/cshperspect.a011189] [PMID: 22952397]
[39]
Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997; 7(4): 261-9.
[http://dx.doi.org/10.1016/S0960-9822(06)00122-9] [PMID: 9094314]
[40]
Kim JE, Lee MR, Park JJ, et al. Quercetin promotes gastrointestinal motility and mucin secretion in loperamide-induced constipation of SD rats through regulation of the mAChRs downstream signal. Pharm Biol 2018; 56(1): 309-17.
[http://dx.doi.org/10.1080/13880209.2018.1474932] [PMID: 29952685]
[41]
Yang Y, Choi PP, Smith WW, et al. Exendin-4 reduces food intake via the PI3K/AKT signaling pathway in the hypothalamus. Sci Rep 2017; 7(1): 6936.
[http://dx.doi.org/10.1038/s41598-017-06951-0] [PMID: 28761132]
[42]
Ju WJ, Zhao ZK, Chen SL, et al. Buzhongyiqi decoction protects against loperamide-induced constipation by regulating the arachidonic acid pathway in rats. Front Pharmacol 2020; 11: 423.
[http://dx.doi.org/10.3389/fphar.2020.00423] [PMID: 32317976]
[43]
Ballard J, Shiner M. Evidence of cytotoxicity in ulcerative colitis from immunofluorescent staining of the rectal mucosa. Lancet 1974; 1(7865): 1014-7.
[http://dx.doi.org/10.1016/S0140-6736(74)90416-4] [PMID: 4133699]
[44]
Hodgson HJF, Potter BJ, Jewell DP. C3 metabolism in ulcerative colitis and Crohn’s disease. Clin Exp Immunol 1977; 28(3): 490-5.
[PMID: 891024]
[45]
Teiberg P, Gjone E. Humoral immune system activity in inflammatory bowel disease Stand J Gastroenterol 1975; 7545-9.
[46]
Moon MR, Parikh AA, Pritts TA, et al Interleukin-1beta induces complement component C3 and IL-6 production at the basolateral and apical membranes in a human intestinal epithelial cell line Shock 2000; 13(5): 374-8.
[http://dx.doi.org/10.1097/00024382-200005000-00005] [PMID: 10807012]

© 2024 Bentham Science Publishers | Privacy Policy